Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Bonnie Ky, MD, MSCE

Assistant Professor of Medicine
Department: Medicine

Contact information
Hospital of the University of Pennsylvania
11-105 Smilow Center for Translational Research
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-573-6606
Fax: 215-746-7415
Education:
BS (Chemical Engineering )
Massachusetts Institute of Technology, 1995.
MD (Medicine)
University of Pennsylvania, 2001.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2009.
Post-Graduate Training
Intern in Medicine, Hospital of the University of Pennsylvania, Philadelphia, 2001-2002.
Resident in Medicine, Hospital of the University of Pennsylvania, Philadelphia, 2002-2004.
Fellowship in Cardiology, Hospital of the University of Pennsylvania, Philadelphia, 2004-2007.
Fellowship, Cardiology Noninvasive Research, Hospital of the University of Pennsylvania, Philadelphia, 2007-2008.
Certifications
Internal Medicine, American Board of Internal Medicine, 2004.
Cardiovascular Medicine, American Board of Internal Medicine, 2007.
Level III Echocardiography, National Board of Echocardiography, 2007.
Level II Nuclear Cardiology, Certification Board of Nuclear Cardiology, 2007.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

My clinical expertise is in noninvasive imaging by echocardiography and the care of patients in cardio-oncology.

Description of Research Expertise

My research interests are in translational cardiovascular epidemiology with a focus on the study of novel signaling pathways and mechanisms in human heart failure, cardiac remodeling, and cancer therapy cardiotoxicity. Current areas of research include:

1) Neuregulin Signaling:
We are interested in defining the relevance of circulating neuregulin as it relates to human heart failure and cardiac remodeling. I am the principal investigator of a longitudinal study determining the association between circulating neuregulin levels and cardiac remodeling and clinical outcomes in the Penn Heart Failure Study and the Chronic Renal Insufficiency Cohort.


2) Mechanistic Biomarker Studies in Cancer Therapy Cardiotoxicity:
We are interested in defining novel circulating biomarkers and genetic variations predictive of cancer therapy cardiotoxicity. Our objective is to gain mechanistic and translational insight into the pathophysiology of this disease. We have ongoing studies in specific pathways and biomarkers of interest, as well as proteomics discovery across various cardiotoxic regimens.


3) Myocardial Mechanics in Cancer Therapy Cardiotoxicity and Heart Failure:
We are interested in gaining insight into alterations in myocardial mechanics and sensitive measures of cardiac function, as defined by echocardiography, in patients exposed to cardiotoxic chemotherapy regimens as well as patients with chronic heart failure.

Selected Publications

Narayan HK, Finkelman BS, French B, Plappert T, Hyman D, Smith AM, Margulies KB, Ky B: Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations with Ejection Fraction Decline, Recovery, and Heart Failure Symptoms over 3 Years of Followup. Circulation 135(15): 1397-1412, April 2017 Notes: Epub 2017 Jan 19.

Aimo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL, Bayes-Genis A, Anand I, Januzzi JL, Emdin M: Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. JACC Heart Failure 5(4): 280-286, April 2017 Notes: Epub 2016 Nov 2.

Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Nayan HK, Ewer S, ElAmm C, Lenihan D, Ky B: Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research Feb 2017 Notes: Epub ahead of print.

Kawut SM, Archer-Chicko CL, DiMichele A, Fritz JS, Klinger JR, Ky B, Palevsky HI, Palmisciano AJ, Patel M, Pinder D, Propert KJ, Smith KA, Stanczyk F, Tracy R, Vaidya A, Whittenhall ME, Ventetuolo CE: Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial. American Journal of Respiratory and Critical Care Medicine 195(3): 360-368, Feb 2017.

O'Farrell ACO, Evans R, Silvola JMU, Miller IS, Conroy E, Hector S, Cary M, Murray D, Jarzabek MA, Maratha A, Alamanou M, Udupi GM, Shiels L, Pallaud C, Saraster A, Liljenback H, Jauhiainen M, Oikonen V, Ducret A, Cutler P, Mc Auliffe F, Rousseau JA, Lecomte R, Gacson S, Ky B, Force T, Arany Z, Knuuti J, Gallagher W, Roivainen A, Byrne AT: A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate. Plos One 12(1): e0169964, Jan 2017 Notes: eCollections 2017.

Narayan HK, Wei W, Feng Z, Lenihan D, Plappert T, Englefield V, Fisch M, Ky B.: Cardiac mechanics and dysfunctionwith anthracyclines in the community: results from the PREDICT study. Open Heart 4(1): e000524, Jan 2017 Notes: eCollection 2017.

Wells QS, Veatch OJ, Fessel JP, Joon AY, Mosley JD, Held EP, Lindsay CS, Shaffer CM, Weeke P, Van Driest SL, Karnes JH, Blair MA, Lagrone LW, Su YR, Bowton EA, Feng Z, Ky B, Lenihan DJ, Fisch MJ, Denny JC, and Roden DM: Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenetics and Genomics 27(7): 247-254, Jul 2017.

Brown JC, Troxel AB, Ky B, Damjanov N, Zemel BS, Rickels MR, Rhim AD, Rustgi AK, Courneya KS, Schmitz KH: Dose-Response Effects of Aerobic Exercise among Colon Cancer Survivors: A Randomized Phase II Trial. Clinical Colorectal Cancer 2017 Notes: Accepted for publication.

Finkelman B, Putt M, Wang T, Wang L,Narayan H, Domchek S, DeMichele A, FOx K, Matro J, Shah P, Clark A, Bradbury A, Narayan V, Carver JR, Tang W, Ky B: Early changes in arginine-nitric oxide metabolites and subsequent cardiac dysfunction in breast cancer patients. Journal of the American College of Cardiology July 2017 Notes: Accepted for publication.

Beer LA, Kossenkov AV, Liu Q, Luning PE, Domchek S, Speicher DW, Ky B: Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. Circulation Research 119(10): 1135-1144, Oct 2016.

back to top
Last updated: 06/26/2017
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration